Sysmex Corporation ADR (OTCMKTS:SSMXY - Get Free Report) was the recipient of a significant decline in short interest during the month of July. As of July 31st, there was short interest totaling 7,400 shares, adeclineof91.9% from the July 15th total of 91,200 shares. Based on an average daily volume of 216,500 shares, the days-to-cover ratio is currently 0.0 days. Currently,0.0% of the company's stock are short sold. Currently,0.0% of the company's stock are short sold. Based on an average daily volume of 216,500 shares, the days-to-cover ratio is currently 0.0 days.
Sysmex Stock Performance
Shares of SSMXY traded down $0.40 during trading hours on Thursday, hitting $13.42. The stock had a trading volume of 59,191 shares, compared to its average volume of 83,465. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.97 and a quick ratio of 2.30. Sysmex has a 12 month low of $13.42 and a 12 month high of $22.00. The firm has a market capitalization of $8.45 billion, a PE ratio of 26.84 and a beta of 1.15. The stock has a fifty day moving average price of $16.52 and a 200 day moving average price of $17.66.
Sysmex (OTCMKTS:SSMXY - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.12 by ($0.07). Sysmex had a return on equity of 10.36% and a net margin of 9.35%. The firm had revenue of $717.09 million during the quarter, compared to the consensus estimate of $807.27 million. Analysts anticipate that Sysmex will post 0.57 EPS for the current year.
About Sysmex
(
Get Free Report)
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sysmex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sysmex wasn't on the list.
While Sysmex currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.